华熙生物赵燕：集团聚焦长寿延衰场景 AI赋能研发制造与C端测肤

This article covers Bloomage Biotech’s latest strategic direction, business adjustments, and consumer-facing service upgrades announced at the 2026 China (International) Fragrance, Flavor & Cosmetics Industry Annual Conference, information directly relevant to general consumers tracking skincare brand developments and selecting suitable products.

1. The company’s core R&D focus has shifted to longevity and anti-aging scenarios, with a cell-level pipeline of active ingredients beneficial to skin health, covering widely recognized skincare and health ingredients including hyaluronic acid, collagen, PDRN, salidroside, and ergothioneine.

2. Its consumer-facing AI skin analysis function is being upgraded: moving beyond simple skin type labels such as dry, oily, or sensitive skin, the tool will deliver more granular, personalized diagnostic results covering ECM status, skin metabolic performance, and other indicators, helping consumers assess their skin conditions more accurately.

3. The company is streamlining its brand portfolio, having discontinued multiple skincare lines including Runxiquan, Runxihe, and Demarun to concentrate resources on core brands such as Biohyalux and QuadHA. Consumers shopping for relevant products may prioritize tracking product iterations under these core brand lines.

As a leading player in the biotech beauty sector, Bloomage Biotech’s strategic adjustments, R&D roadmaps, and brand operation approaches carry significant reference value for industry brand owners.

1. In terms of consumer trends and brand narrative, the industry is shifting from single-ingredient messaging to systematic, science-backed storytelling. Bloomage has moved beyond its past raw material-focused narrative to a cell science-centered framework, building a full-cycle anti-aging system covering ECM health, intercellular communication, and intracellular wellness aligned with the long-term growth trajectory of anti-aging consumer demand.

2. On brand operation, amid performance pressure that saw its dermatology business revenue drop 50.88% year-on-year in the first half of the year, Bloomage has adopted a streamlining strategy, discontinuing non-core skincare brands including Runxiquan, Runxihe, and Demarun to redirect resources to core brands with established user recognition such as Biohyalux and QuadHA, avoiding resource dilution across an overextended brand matrix.

3. For product R&D, the company leverages its in-house AI model to shorten active ingredient development cycles from years to months. It is also rolling out granular AI skin diagnostic tools on the consumer end to deliver more precise personalized assessments and strengthen user engagement.

Bloomage Biotech’s strategic pivot and business adjustments highlight clear demand directions, replicable operational tactics, and avoidable operational risks for sellers in the beauty and broader wellness sectors.

1. Consumer demand opportunities: Longevity and anti-aging represent a confirmed long-term growth track. User anti-aging demands have evolved from surface-level skincare to cell-level, full-cycle wellness, creating substantial market space for products containing active ingredients targeting ECM repair, intercellular communication regulation, and intracellular nourishment, including formulations with hyaluronic acid, collagen, PDRN, ergothioneine, and salidroside.

2. Replicable operational tactics: First, concentrate resources on core products and brands with established user recognition, and promptly sunset underperforming non-core lines to improve resource efficiency. Second, replace simplistic traditional skin type classifications with granular AI skin analysis tools to deliver personalized solutions and boost conversion rates.

3. Risk alerts: Guard against pitfalls from overextended multi-brand operations and poor alignment between legacy and new business lines, which can lead to insufficient backup growth drivers when core business revenue declines. Monitor operational uncertainties arising from core talent turnover and supply chain volatility.

Bloomage Biotech’s R&D, manufacturing upgrade paths, and business direction adjustments provide clear demand signals for upstream and midstream supply chain factories, as well as a replicable reference framework for digital transformation.

1. Product design and production demand signals: Demand for products in the longevity and anti-aging track continues to grow. There are clear downstream order opportunities for cell-level anti-aging active ingredients, including hyaluronic acid and collagen for ECM structure building, PDRN for intercellular communication regulation, and salidroside and ergothioneine for intracellular action, as well as supporting end products. Bloomage has screened more than 50,000 medicinal and edible homologous formulas, roughly one-third of which are skin-related; these skin-nourishing medicinal-edible products also represent a key future production direction.

2. Insights for digital production upgrades: Factories can accumulate historical production data, including parameters such as temperature, humidity, dissolved oxygen, and metabolic status during fermentation or processing, and reference Bloomage’s "AI pilot smart brain" model to build AI-powered production systems. These systems can predict production status in advance, intervene in abnormalities, and form a closed production loop covering knowledge accumulation, solution generation, experimental verification, and result feedback, improving pilot and mass production efficiency and shortening new product launch cycles.

3. Commercial opportunity notes: Leading biotech firms are streamlining non-core brands to focus on core product lines, creating openings for factories to proactively engage with core brands’ supply chain demands and secure long-term, stable partnership opportunities.

Bloomage Biotech’s transformation moves and technology application directions clearly illustrate development trends, core client pain points, and business entry opportunities for service providers in the biotech beauty industry.

1. Industry development trends: Biotech beauty companies are comprehensively pivoting to the longevity and anti-aging track, with full-value-chain AI empowerment as a confirmed development direction. Demand for intelligent upgrades across R&D, manufacturing, and consumer-facing services is strong.

2. Core client pain points: First, R&D efficiency requires improvement: traditional active ingredient development runs on multi-year cycles, and enterprises need tools to shorten R&D timelines and accurately screen active ingredients and formulations suited for skin health. Second, manufacturing remains insufficiently intelligent: production processes rely heavily on manual experience, making it difficult to predict abnormalities in advance and leading to low pilot stage efficiency. Third, consumer-facing services lack granularity: traditional skin type classifications are overly broad to match users’ personalized skin diagnostic needs. Fourth, enterprises in transition commonly face operational pain points including resource dilution across multi-brand matrices and poor alignment between legacy and new business lines.

3. Solution directions: Service providers can design offerings around AI R&D model building, smart production system deployment, granular AI skin analysis tool development, and brand resource integration consulting to match the upgrade demands of industry clients.

As a leading brand owner in the beauty and wellness track, Bloomage Biotech’s business adjustments and strategic direction provide clear reference points for e-commerce platforms on merchant recruitment, category operation, and risk management.

1. Merchant recruitment and category operation directions: Longevity and anti-aging is a high-potential category worthy of targeted support. Cell-level, full-cycle anti-aging products, including skincare and wellness items formulated with active ingredients such as hyaluronic acid, collagen, PDRN, ergothioneine, and salidroside, as well as supporting personalized services such as AI skin analysis, should be prioritized for merchant recruitment and resource allocation. For brand partnerships, platforms can prioritize engagement with head brands that receive concentrated corporate resources, such as Biohyalux and QuadHA, to boost the competitiveness of core platform categories.

2. Platform service upgrade directions: Brand owners have strong demand for AI tools for R&D and user operation. Platforms can open up relevant technical capabilities to help brands build granular user diagnostic systems and improve user conversion efficiency.

3. Risk avoidance notes: During brand onboarding and operation, platforms should screen for operational risks of non-core brands under large multi-brand matrices, monitor store instability risks arising from brand owners’ business contraction, shareholder stake reductions, and core talent turnover, and prepare response plans in advance.

Bloomage Biotech’s strategic transformation and current operational status reflect the latest development trends, existing challenges, and business model evolution directions of China’s domestic biotech beauty industry, carrying high industry research value.

1. Emerging industry trends: First, leading biotech firms are undergoing a narrative shift, moving from past single-ingredient messaging to a systematic framework centered on cell science. Focused on longevity and anti-aging scenarios, these firms are building full-cycle anti-aging product systems covering ECM health, intercellular communication, and intracellular wellness. Second, AI technology is being integrated across the entire industry value chain: from active ingredient prediction and screening of more than 50,000 medicinal-edible homologous formulas on the R&D end, to production parameter prediction and intelligent intervention in manufacturing, to granular skin analysis services for consumers, full-chain AI empowerment is reshaping industry efficiency. For example, Bloomage’s AI model has cut active ingredient development cycles from years to months.

2. Emerging industry challenges: Leading enterprises in transition commonly face pain points from poor alignment between legacy and new business lines. For instance, Bloomage’s current skincare business revenue has fallen 50.88% year-on-year, with its raw material business becoming its largest revenue segment for the first time, while new growth drivers have not fully taken over. Uncertainties remain, including core technical talent turnover and continuous stake reductions by its second largest shareholder, China Life Chengda, leaving the outcome of its transformation to be observed. Additionally, competition among industry leaders for discourse power over core ingredients is intensifying, as seen in the 2025 market and narrative rivalry between Bloomage Biotech and Giant Biogene over hyaluronic acid and recombinant collagen.